Alternative Data for Minerva Neurosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 11 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 9,622 | Sign up | Sign up | Sign up |
| X Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Minerva Neurosciences
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products for the treatment of diseases of the central nervous system. The company is headquartered in Waltham, Massachusetts.
| Price | $7.94 |
| Target Price | Sign up |
| Volume | 588,635 |
| Market Cap | $27M |
| Year Range | $1.63 - $8 |
| Dividend Yield | 0% |
| PE Ratio | 2.51 |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia - SlideshowFebruary 3 - SeekingAlpha |
|
Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia TranscriptFebruary 3 - SeekingAlpha |
 |
Top stock movements in today's session.March 9 - ChartMill |
 |
12 Health Care Stocks Moving In Monday's After-Market SessionMarch 9 - Benzinga |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 1,400 | -1,400 | -2.7M | -2.7M | -0.363 |
| Q2 '25 | 0 | 1,400 | -1,400 | -3.3M | -3.3M | -0.430 |
| Q1 '25 | 42,000 | 21,000 | 21,000 | -3.8M | -4.3M | -0.500 |
| Q4 '24 | 42,000 | 21,000 | 21,000 | -4.3M | -4.3M | -0.560 |
| Q3 '24 | 0 | 5,600 | -5,600 | 23M | 23M | 2.970 |
Insider Transactions View All
| Luthringer Remy filed to sell 68,994 shares at $3.8. May 2 '23 |
| Ahlholm Frederick W filed to sell 17,518 shares at $4.5. May 2 '23 |
| Race Geoff filed to sell 51,324 shares at $3.9. May 2 '23 |
| Luthringer Remy filed to sell 72,635 shares at $3.9. May 2 '23 |
Similar companies
Read more about Minerva Neurosciences (NERV) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions & customer reviews.
FAQ - Minerva Neurosciences
The Market Cap of Minerva Neurosciences is $27M.
As of today, Minerva Neurosciences' PE (Price to Earnings) ratio is 2.51.
Currently, the price of one share of Minerva Neurosciences stock is $7.94.
The NERV stock price chart above provides a comprehensive visual representation of Minerva Neurosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Minerva Neurosciences shares. Our platform offers an up-to-date NERV stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Minerva Neurosciences (NERV) does not offer dividends to its shareholders. Investors interested in Minerva Neurosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Minerva Neurosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
